Special Issue

The Genetic Differences among Colistin-Resistant *Enterobacterales*, *Acinetobacter* spp. and *Pseudomonas aeruginosa*

Message from the Guest Editors

Colistin is one of the few remaining antimicrobials able to be used as last resort against severe infections caused by *Enterobacterales, Acinetobacter* spp. and *Pseudomonas aeruginosa*. This Special Issue will focus on these bacteria. The aim is to present original research or review manuscripts dealing with different aspects of colistin resistance: molecular epidemiology and dissemination of colistin-resistant pathogens; molecular mechanisms of resistance and genetic acquisition; diagnostics; antimicrobial regimen–antimicrobial therapy. Particular consideration will be given to transdisciplinary research focused on the development of molecular, cellular, microbiological, computational and epidemiological approaches to addressing pathogen drug resistance. Studies assessing interactions among multi- and pan-drug resistance phenotypes and their genetic basis are encouraged, along with those examining the genomic and evolutionary context of mobilized, amplified or rearranged drug resistance genes. Lastly, papers bridging molecular diagnostics and surveillance of genetic elements associated with drug resistance would be appreciated.

Guest Editors

Dr. Spyros Pournaras
Prof. Dr. Raffaele Zarrilli
Prof. Dr. Katy Jeannot

Deadline for manuscript submissions

closed (31 March 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/97727

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI